ARGN 21.08 is up 11% on earnings. It looks expensive to me but that is only a casual observation. No dd.
Amerigon Reports 2007 Third Quarter, Nine-Month Results Tuesday October 30, 6:00 am ET Year-over-Year Revenues Increase 25% and 33%, Respectively; Earnings before Income Tax Up 36% and 55%
NORTHVILLE, Mich., Oct. 30 /PRNewswire-FirstCall/ -- Amerigon Incorporated (Nasdaq: ARGN - News), a leader in developing and marketing products based on advanced thermoelectric (TE) technologies for a wide range of global markets and applications, today announced that for the third quarter and nine months ended September 30, 2007, revenues were up 25 percent and 33 percent, respectively, over the same periods in 2006, and earnings before income tax rose year-over-year 36 percent and 55 percent, respectively.
ADVERTISEMENT click here Strong demand for the Company's proprietary Climate Control Seat(TM) (CCS(TM)) system drove revenues for this year's third quarter and first nine months to $15.9 million and $47.2 million, respectively, up from $12.7 million and $35.6 million in last year's third quarter and first nine months. Gross margins as a percentage of revenue for the 2007 third quarter were 32.5 percent compared with 32.7 percent in the prior year quarter and for the first nine months of this year, gross margins improved to 32.9 percent, up from 31.9 percent in the year-earlier period. Earnings before income tax for the third quarter and first nine months of 2007 increased 36 percent and 55 percent, respectively, to $2.0 million and $6.2 million from $1.5 million and $4.0 million in the prior year periods.
During this year's third quarter, Amerigon recorded a deferred research and development (R&D) tax benefit of approximately $1.7 million following a study of its research and development activities and related expenses for the period from 1999 through 2006. The Company expects that it will qualify for further R&D credits during 2007.
Net income for this year's third quarter was $3.1 million, or $0.14 per basic and $0.13 per diluted share, compared with net income in last year's third quarter of $900,000, or $0.04 per basic and diluted share. Excluding the R&D credits, net income for this year's third quarter was $1.3 million, or $0.06 per basic and diluted share. Net income for the first nine months of 2007 was $5.6 million, or $0.26 per basic and $0.25 per diluted share, compared with net income for the year-earlier period of $2.5 million, or $0.12 per basic and $0.11 per diluted share. Excluding the R&D credits, net income for the first nine months of 2007 was $3.9 million, or $0.18 per basic and $0.17 per diluted share.
Before recording the prior period R&D credits, Amerigon recorded a tax provision equal to 37 percent of pretax earnings in this year's third quarter and first nine months, which compares to 38 percent in the prior year periods. This expense was substantially a non-cash deferred provision since the Company had significant net operating losses during its development stage that substantially offset current tax payments.
President and Chief Executive Officer Daniel R. Coker said, "We had another very good quarter, and we are continuing to have a very good year in 2007. We are achieving the goals we set out for our CCS business in 2007 and are making progress on new applications for our TE technology. As a result, our revenues are growing and expanding as we have predicted, and our bottom line is following along the same path."
Coker noted that the "take rates," which are the rates that a feature like CCS are chosen by the car buying customers, continue to reflect high acceptance, and are solid and promising. He also added that the Company is getting better penetration in Asia and Europe, a trend that should continue through at least 2008.
The Company's balance sheet as of September 30, 2007 remained strong with cash, cash equivalents and short-term investments of $20.4 million, total assets of $52.4 million, no bank debt and shareholders' equity of $40.1 million.
With the addition during the quarter of the second Jaguar vehicle to offer CCS, the 2009 Jaguar XF luxury sports sedan, CCS is available on 22 vehicle models produced by Ford, General Motors, Toyota, Nissan and Hyundai. Coker noted that Amerigon is making excellent progress toward completing preproduction activities for additional 2008 model year vehicles and winning new contracts for future model year programs.
"We have a lot of programs in play for 2008, and we're doing a lot of hard work to get ready to launch on schedule. We look forward to very strong growth at an increasing rate in 2008," added Coker.
Unit shipments of CCS systems for the 2007 third quarter and first nine months increased to 234,000 and 697,000, respectively, up from 179,000 units and 494,000 units for the year-earlier periods.
Fully diluted weighted average shares outstanding for the 2007 third quarter and nine months were 22,748,000 and 22,555,000, respectively, compared with 22,141,000 and 20,193,000 in the prior year periods.
Coker said that the Company's BSST subsidiary continues to be focused on expanding the use of its proprietary thermoelectric technologies and has several products under development that should lead to applications in a variety of automotive and non-automotive markets. BSST is receiving serious interest in its automotive power generation technology developed in cooperation with the Department of Energy and other partners in light of the European Community's plan to institute a carbon tax as early as practicable.
Guidance for 2007 & 2008
Reflecting results in the first nine months of 2007 and the outlook for the balance of this year, Amerigon is confirming its earlier guidance at the top of the previously announced range with a year-over-year increase in CCS revenues in 2007 of about 25 percent, coupled with continued increases in profitability.
Coker also said that the Company expects CCS revenue growth in 2008 of 30 to 40 percent with continued strong increases in profitability. There are a number of macro-economic and geopolitical issues outside Amerigon's control, such as the effects of gas price increases, the uncertainty of the situations in the Middle East and the Gulf Region, and the availability of credit, that could negatively impact the automotive industry, the overall economy and Amerigon's results.
Conference Call
As previously announced, Amerigon is conducting a conference call today to be broadcast live over the Internet at 11:30 AM Eastern Time to review the financial results for the third quarter and nine months ended September 30, 2007. The dial-in number for the call is 1-888-469-4228. The live webcast and archived replay of the call can be accessed in the Events page of the Investor section of Amerigon's website at http://www.amerigon.com.
About Amerigon
Amerigon (Nasdaq: ARGN - News) develops products based on its advanced, proprietary, efficient thermoelectric (TE) technologies for a wide range of global markets and heating and cooling applications. The Company's current principal product is its proprietary Climate Control Seat(TM) (CCS(TM)) system, a solid-state, TE-based system that permits drivers and passengers of vehicles to individually and actively control the heating and cooling of their respective seats to ensure maximum year-round comfort. CCS, which is the only system of its type on the market today, uses no CFCs or other environmentally sensitive coolants. Amerigon maintains sales and technical support centers in Southern California, Detroit, Japan, Germany and England.
Certain matters discussed in this release are forward-looking statements that involve risks and uncertainties, and actual results may be different. Important factors that could cause the Company's actual results to differ materially from its expectations in this release are risks that sales may not significantly increase, additional financing, if necessary, may not be available, new competitors may arise and adverse conditions in the automotive industry may negatively affect its results. The liquidity and trading price of its common stock may be negatively affected by these and other factors. Please also refer to Amerigon's Securities and Exchange Commission filings and reports, including but not limited to its Form 10-Q for the period ended September 30, 2007 and its Form 10-K for the year ended December 31, 2006.
AMERIGON INCORPORATED
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited)
Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 Product revenues $15,909 $12,729 $47,240 $35,579 Cost of sales 10,736 8,570 31,698 24,229 Gross margin 5,173 4,159 15,542 11,350
Operating expenses: Research and development 1,990 1,811 5,585 4,973 Research and development reimbursements (619) (815) (1,731) (2,451) Net research and development expenses 1,371 996 3,854 2,522 Selling, general and administrative 2,119 1,869 6,295 5,311 Total operating expenses 3,490 2,865 10,149 7,833 Operating income 1,683 1,294 5,393 3,517
Interest income 251 135 681 365 Other income 39 21 139 121 Earnings before income tax 1,973 1,450 6,213 4,003
Income tax expense (benefit) (1,083) 550 607 1,519 Net income $3,056 $900 $5,606 $2,484
Basic earnings per share: Common Stock $0.14 $0.04 $0.26 $0.12 Convertible Preferred Stock $0.12 Diluted earnings per common share $0.13 $0.04 $0.25 $0.11
Weighted average number of shares -- basic Common Stock 21,701 21,282 21,575 19,387 Convertible Preferred Stock (as converted) 1,875 Weighted average number of shares -- diluted 22,748 22,141 22,555 20,193
AMERIGON INCORPORATED
CONSOLIDATED CONDENSED BALANCE SHEETS (In thousands, except share data)
September 30, December 31, ASSETS 2007 2006 (unaudited) Current Assets: Cash & cash equivalents $1,795 $2,440 Short-term investments 18,650 12,076 Accounts receivable, less allowance of $269 and $227, respectively 12,701 9,329 Inventory: Raw materials 200 655 Finished goods 1,203 3,714 Inventory 1,403 4,369 Deferred income tax assets 3,900 3,839 Prepaid expenses and other assets 1,148 284 Total current assets 39,597 32,337
Property and equipment, net 3,507 1,986 Deferred financing costs 10 12 Patent costs, net of accumulated amortization of $60 and $18, respectively 2,607 835 Deferred income tax assets 6,684 7,226 Total assets $52,405 $42,396
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities: Accounts payable $8,204 $5,615 Accrued liabilities 3,363 2,757 Deferred manufacturing agreement -- current portion 200 200 Total current liabilities 11,767 8,572 Deferred manufacturing agreement -- long-term portion 500 650 Total liabilities 12,267 9,222
Shareholders' equity: Common Stock: No par value; 30,000,000 shares authorized, 21,735,633 and 21,335,188 issued and outstanding at September 30, 2007 and December 31, 2006, respectively 62,396 61,606 Paid-in capital 21,595 21,024 Accumulated other comprehensive income -- foreign currency (15) (12) Accumulated deficit (43,838) (49,444) Total shareholders' equity 40,138 33,174 Total liabilities and shareholders' equity $52,405 $42,396
AMERIGON INCORPORATED
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
Nine Months Ended June 30, 2007 2006 Operating Activities: Net income $5,606 $2,484 Adjustments to reconcile net income to cash provided by operating activities: Deferred tax provision 483 1,438 Stock option compensation 571 317 Depreciation and amortization 433 371 Loss on disposal of property and equipment 11 33 Changes in operating assets and liabilities: Accounts receivable (3,373) (4,023) Inventory 2,965 (2,223) Prepaid expenses and other assets (865) (100) Accounts payable 2,549 1,691 Accrued liabilities 994 217 Net cash provided by operating activities 9,374 205
Investing Activities: Purchases of short-term investments (29,137) (11,400) Sales of short-term investments 22,563 12,325 Purchase of long-term investments - (659) Purchase of property and equipment (2,070) (1,129) Proceeds from property and equipment sales - 2 Patent costs (1,813) (255) Net cash used in investing activities (10,457) (1,116)
Financing Activities: Checks issued in excess of bank balance 40 615 Proceeds from the exercise of Common Stock options 401 165 Net cash provided by financing activities 441 780
Foreign currency effect (3) (14) Net decrease in cash and cash equivalents (645) (145) Cash and cash equivalents at beginning of period 2,440 1,364 Cash and cash equivalents at end of period $1,795 $1,219
Supplemental disclosure of non-cash transactions: Issuance of Common Stock under the 2006 Equity Incentive Plan $389 $- Cash paid for Taxes $187 $121
Contact: Allen & Caron Inc Jill Bertotti (investors) jill@allencaron.com Len Hall (media) len@allencaron.com (949) 474-4300
Market Data 
Markets 
AI
